Merck discontinues development of possible COVID-19 vaccines following results
Kenilworth-based Merck has announced the company is discontinuing development of its COVID-19 vaccine candidates, V590 and V591.
News 12 Staff
•
Jan 25, 2021, 11:56 PM
•
Updated 1,180 days ago
Share:
More Stories
Hometown Heroes in New York City
2ds ago
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
200ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
212ds ago1:54
Hochul: Updated COVID vaccine to be available in NY in the coming days
219ds ago2:22
New and rare COVID variant detected in NYC wastewater; Gov. Hochul urges caution
233ds ago2:39
City health officials: COVID-19 cases on the rise as new variant emerges
234ds agoHometown Heroes in New York City
2ds agoNobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
200ds ago0:21
Biden administration announces $600M to produce COVID tests and will reopen website to order them
212ds ago1:54
Hochul: Updated COVID vaccine to be available in NY in the coming days
219ds ago2:22
New and rare COVID variant detected in NYC wastewater; Gov. Hochul urges caution
233ds ago2:39
City health officials: COVID-19 cases on the rise as new variant emerges
234ds agoKenilworth-based Merck has
announced the company is discontinuing development of its COVID-19 vaccine
candidates, V590 and V591.
The decision follows the company’s
review of findings from Phase 1 clinical studies for the vaccines.
In the studies, both V590
and V591 were generally well tolerated, but the immune responses were inferior
to those seen following natural infection and those reported for other
SARS-CoV-2/COVID-19 vaccines.
The company now plans to
focus its COVID-19 research strategy and production capabilities on advancing
two therapeutic candidates, MK-4482 and MK-7110.
For more information, click
here.
